The Drugs That Changed Our Minds

Home > Nonfiction > The Drugs That Changed Our Minds > Page 44
The Drugs That Changed Our Minds Page 44

by Lauren Slater

Rosenbaum, Marsha 280–1

  Rosenhan, David 331, 332

  Ross, Stephen 256, 260

  Rowell Laboratories 105

  Rufus of Ephesus 207, 208

  Sabbagh, Karl 211

  Sackheim, Harold 311

  Sacktor, Todd 292, 294, 295–6, 297, 298

  Sakel, Manfred 12, 13

  Salzman, Carl 153

  Sassyfras 280

  Schacter, Daniel 299

  Schildkraut, Joseph 157–8

  schizophrenia 11, 18, 129–30

  anatomic theories of 52

  chlorpromazine therapy see chlorpromazine

  deep sleep therapy 14

  dopamine hypothesis 52, 53, 176, 191, 328

  double-bind theory of 49

  incidence of 54

  insulin coma therapy 13

  lithium therapy 80, 83, 110

  LSD therapy 275

  pentylenetetrazol therapy 13–14

  psychosurgery 15–16

  Schmidlin, Paul 130

  Schou, Mogens 86, 87, 88, 91–2, 95, 98, 99–104, 105, 110

  self-harming 118, 120, 179, 335

  Senning, Åke 325

  serotonin 17, 50–1, 54, 139, 142, 144, 145, 157, 158, 161–2, 172, 175, 191, 194

  low-serotonin hypothesis 144–5, 148, 328, 330

  sertraline 85, 171

  7UP soft drink 63

  sex addicts 180–1

  Sexton, Anne 93

  sexual dysfunction 174–6, 180–3

  Shadyac, Tom 167

  sham acupuncture 231–2

  sham surgery 219–23

  shamanic traditions 242–3, 265, 339, 342

  Shapiro, Arthur and Elaine 214

  Shepherd, Michael 100–1, 102, 103, 104, 105

  Shorter, Edward 199

  Shriver, Lionel 185

  Shuge, Kelly and Thomas 269–71, 278

  Shulgin, Alexander 272

  Shulgin, Ann 272

  Sigwald, Jean 34

  Smith, Gwenn 303

  Smith, Huston 254–5, 261

  Smith, Kline & French 39, 40, 41, 45, 47, 48, 105

  smoking addiction 264

  SNRIs (serotonin and noradrenaline reuptake inhibitors) 178, 334

  social anxiety 5, 173, 274

  spas and springs 64–5

  spectrophotofluorometer 50, 51

  spectrophotometer 88, 99

  Spitzer, Robert 332

  spontaneous remission 79

  SSRIs (selective serotonin reuptake inhibitors) 4–5, 85, 93, 157–209, 314, 341–2

  author’s experience of 178–9, 202–4, 334

  earliest 157–9

  efficacy, limits on 319, 342

  long- and mid-term studies on 171–2

  numbing effects 177, 178, 184, 200

  rising doses 202–3

  and sexual dysfunction 174–6, 180–3

  side effects 171, 172, 174–6, 177, 178, 181–2, 184, 200, 203, 342

  tolerance problem 334

  withdrawal effects 201, 204

  see also specific index entries

  statins 54

  Strömgren, Erik 86, 110

  suicide and suicidal feelings 148, 165–6, 167, 185, 230, 311, 317, 336, 338

  sulphonamides 67

  sumatriptan 217

  summer blue 125, 127

  surgical shock 23–4

  synaptic cleft 145, 158, 172, 191, 194

  Szasz, Thomas 54, 56, 57, 193

  talking therapies 6, 17, 40, 223–8, 339

  see also cognitive behavioural therapy (CBT);

  psychoanalysis; psychotherapy

  tardive dyskinesia 48, 54, 154

  Teicher, Martin 185

  thiopental 29

  Thompson, J. Anderson 181, 183, 184

  Thorazine 12, 18, 25, 40

  see also chlorpromazine

  Thuillier, Jean 38

  Tofranil 139

  see also imipramine

  trans-cranial magnetic stimulation (TMS) 222

  transmyocardial laser revascularisation (TMR) 220–1

  tranylcypromine 149

  traumatic memories 290–3, 297, 298

  see also post-traumatic stress disorder

  tricyclics 124, 125, 127, 140, 145, 150, 151, 157, 160, 197, 200–1, 330, 334

  side effects 146

  see also imipramine

  Trivers, Robert 218

  turpentine injections 15

  tyramine 146, 150

  unipolar disorder 76

  United States

  antipsychotic use 54

  incidence of depression in 162–3

  mental hospitals 12

  Ure, Alexander 64

  urea, synthesising of 124–5

  uric acid 62–4, 65, 66, 67, 68–9, 72

  Utena, Hiroshi 57

  vagus nerve stimulation (VNS) 222

  Val-de-Grâce military hospital 22, 23, 28, 29–31

  Valenstein, Elliot 12

  Valium 197

  valproate 111

  valproate semisodium 111, 126

  Velez, Maria Eugenia 294–5

  venlafaxine 3, 171, 178, 203, 285, 334

  veratrine 16

  Vincent, Carol 237–8, 261, 262–3, 264, 266

  voodoo death 228–9

  Vuckovic, Alexander 55, 111, 113

  Waldron, A.M. 98

  Wallace, David Foster 146–8

  Wasson, R. Gordon 241–3

  Wesbecker, Joseph 186–7, 189

  West, Louis Jolyon 309

  Whitaker, Robert 190, 191–2, 193, 195, 334

  Wiesel, Elie 299

  Winfrey, Oprah 282

  Wöhler, Friedrich 124–5

  Wong, David T. 159

  Yin, Jerry 294

  Young, R.M. 83, 86, 99

  Zeff, Leo 272

  Zelmid 158

  zimelidine 158, 159

  ZIP (zeta inhibitory peptide) 296–8, 299–302

  ziprasidone 53

  Zyprexa 79, 95, 96

  First published in the United States by Little, Brown and Company, 2018

  First published in Great Britain by Simon & Schuster UK Ltd, 2018

  A CBS COMPANY

  Copyright © Lauren Slater, 2018

  The right of Lauren Slater to be identified as the author of this work has been asserted in accordance with the Copyright, Designs and Patents Act, 1988.

  Simon & Schuster UK Ltd

  1st Floor

  222 Gray’s Inn Road

  London WC1X 8HB

  www.simonandschuster.co.uk

  www.simonandschuster.com.au

  www.simonandschuster.co.in

  Simon & Schuster Australia, Sydney

  Simon & Schuster India, New Delhi

  The author and publishers have made all reasonable efforts to contact copyright-holders for permission, and apologise for any omissions or errors in the form of credits given. Corrections may be made to future printings.

  A CIP catalogue record for this book is available from the British Library

  Hardback ISBN: 978-1-4711-3688-7

  Trade Paperback ISBN: 978-1-4711-3689-4

  eBook ISBN: 978-1-4711-3691-7

  Typeset in the UK by M Rules

  Printed and bound by CPI Group (UK) Ltd, Croydon, CR0 4YY

  Simon & Schuster UK Ltd are committed to sourcing paper that is made from wood grown in sustainable forests and support the Forest Stewardship Council, the leading international forest certification organisation. Our books displaying the FSC logo are printed on FSC certified paper.

 

 

 
ass="sharethis-inline-share-buttons">share



‹ Prev